SIBO and Multiple Sclerosis: Autoimmunity Meets Gut Health

Multiple sclerosis (MS) is an autoimmune condition in which the immune system attacks the myelin sheath protecting nerve fibers in the brain and spinal cord. It affects approximately 2.9 million people worldwide and is associated with a wide range of symptoms including fatigue, mobility impairment, cognitive difficulties, bladder and bowel dysfunction, and pain. What many people with MS don't know is that SIBO is significantly more prevalent in this population than in the general public, and the relationship between gut health and MS disease activity is becoming an increasingly important area of research. The gut microbiome is not a passive bystander in MS — it is an active participant.

MS as an Autoimmune Condition: The Gut Connection

The gut is home to approximately 70-80% of the immune system. Gut-associated lymphoid tissue (GALT) and the intestinal microbiome together train and regulate immune responses throughout the body. When the gut lining is compromised — as it is in SIBO, where bacterial toxins and undigested food particles increase intestinal permeability — immune activation at the gut level can have systemic consequences. For someone with MS, whose immune system is already dysregulated, this additional immune activation from gut permeability is particularly relevant.

Research has found consistent microbiome alterations in MS patients compared to healthy controls: reduced Prevotella, reduced Faecalibacterium prausnitzii (a key anti-inflammatory butyrate producer), increased Akkermansia at certain disease stages, and an overall reduction in microbial diversity. These shifts are not just correlational — germ-free mice colonized with gut bacteria from MS patients develop more severe experimental autoimmune encephalomyelitis (EAE), the animal model of MS, compared to mice colonized with bacteria from healthy donors. The microbiome is actively shaping immune behavior in MS.

SIBO Prevalence in MS

Several factors make MS patients particularly vulnerable to SIBO. First, the neurological damage MS causes to the autonomic nervous system frequently impairs gut motility — the same MMC dysfunction seen in other neurological conditions. Studies have found that autonomic neuropathy is common in MS and correlates with GI transit abnormalities including delayed gastric emptying and slowed small intestinal transit. Second, the mobility limitations associated with MS reduce physical activity, which independently affects gut motility. Third, medication use in MS — particularly opioids for pain management and anticholinergics for bladder control — both have gut-slowing effects that compound the neurological motility impairment.

A 2019 study in the journal Nutrients found that MS patients had significantly higher rates of self-reported GI symptoms including bloating, gas, abdominal pain, and irregular bowel habits compared to age-matched controls. Formal prevalence data on breath-test-confirmed SIBO specifically in MS is limited, but the mechanistic factors are robust — virtually every risk factor for SIBO is over-represented in this population.

Disease-Modifying Therapies and Gut Health

Disease-modifying therapies (DMTs) — the medications that reduce MS relapse rates and slow disease progression — have varying effects on the gut. Interferons (interferon beta-1a/1b) commonly cause nausea, diarrhea, and liver enzyme elevations that affect digestive function. Dimethyl fumarate (Tecfidera) has significant GI side effects as its most common adverse effect, including flushing, nausea, diarrhea, and abdominal pain that affects adherence in up to 30% of patients. Natalizumab and ocrelizumab (the high-efficacy agents) tend to have fewer GI side effects but affect systemic immunity in ways that alter gut immune surveillance.

Importantly, the broad immunosuppression used in MS treatment — particularly with highly effective DMTs — affects the gut-associated immune system along with systemic immunity. This can alter the immune pressure on gut bacterial populations, potentially shifting the microbiome in ways that are not yet well characterized. When evaluating and managing SIBO in MS patients, DMT type, dose, and GI side effect profile are all relevant considerations. A gastroenterologist working with an MS patient should always review the complete medication list.

B12 Deficiency: A Critical Overlap

Vitamin B12 deficiency is a crucial area of overlap between SIBO and MS. SIBO impairs B12 absorption in the terminal ileum, where bacteria compete with and consume B12 before it can be absorbed. B12 deficiency causes neurological symptoms — tingling, numbness, weakness, fatigue, cognitive impairment — that are virtually identical to MS symptoms. This creates a dangerous diagnostic trap: B12 deficiency neurological symptoms in an MS patient can be attributed to MS disease activity rather than to a treatable deficiency.

Additionally, B12 is essential for myelin synthesis. In a patient with MS, where myelin is already being attacked and damaged, B12 deficiency removes one of the body's key resources for myelin repair. Testing serum B12, methylmalonic acid (a more sensitive marker), and homocysteine is important in all MS patients, particularly those with SIBO. When deficiency is identified, intramuscular B12 injections may be needed to bypass the gut absorption problem caused by SIBO.

Bladder and Bowel Dysfunction in MS

Bladder and bowel dysfunction affects approximately 80% of people with MS at some point during their disease course. Neurogenic bladder — with symptoms of urinary urgency, frequency, incontinence, or retention — is managed with anticholinergic medications (oxybutynin, tolterodine, solifenacin) that slow smooth muscle activity. These medications don't discriminate: they slow the bowel as well as the bladder, contributing to constipation and slowed intestinal transit that worsens SIBO and makes it harder to treat.

Bowel dysfunction in MS includes both constipation (more common, related to slowed transit and pelvic floor dysfunction) and fecal urgency/incontinence (related to rectal and sphincter control impairment). SIBO-related symptoms — bloating, gas, altered bowel habits — layer on top of MS bowel dysfunction in ways that can be very difficult to parse. Careful symptom history and targeted testing (breath testing for SIBO, anorectal manometry for sphincter dysfunction) help direct appropriate management.

Gut Health as Part of MS Management

The evidence base for gut-directed interventions in MS is growing. Mediterranean dietary patterns, which reduce gut permeability and support beneficial microbiome species, are associated with lower relapse rates and better quality of life in observational MS studies. Probiotic supplementation has shown modest benefits in some MS trials, particularly Lactobacillus and Bifidobacterium combinations. Butyrate supplementation and dietary approaches that support butyrate-producing bacteria (fermented foods, soluble fiber) are being studied as microbiome-targeted interventions.

For MS patients with confirmed SIBO, treating the overgrowth offers a potential to reduce one of the gut-to-brain inflammatory pathways that may be contributing to disease activity. This doesn't mean SIBO treatment replaces DMT therapy — it doesn't. But addressing SIBO as part of a comprehensive MS management plan, alongside appropriate disease-modifying therapy, nutrition optimization, and physical rehabilitation, represents a holistic approach to a condition where every contributor to inflammation matters.

**Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new treatment or making changes to your existing treatment plan.